| Identification | Back Directory | [Name]
(5alpha,8alpha,9alpha)-5,8,9,10-tetrahydro-5,9-methanobenzocycloocten-8-ylammonium chloride | [CAS]
67384-25-2 | [Synonyms]
Org-6906 free
(5alpha,8alpha,9alpha)-5,8,9,10-tetrahydro-5,9-methanobenzocycloocten-8-ylammonium chloride | [EINECS(EC#)]
266-675-0 | [Molecular Formula]
C13H16ClN | [MDL Number]
MFCD32182626 | [MOL File]
67384-25-2.mol | [Molecular Weight]
221.726 |
| Hazard Information | Back Directory | [Description]
Org-6906 is a dual of monoamine uptake inhibitor and α2 adrenoceptor antagonist potentially for the treatment. Org-6906 facilitated potassium-stimulated release of noradrenaline from slices of cortex, displaced [3H]rauwolscine and [3H]dihydroergocryptine from their binding sites but only weakly blocked alpha 1-adrenoceptors. The alpha 2-adrenolytic properties were also apparent in behavioural interaction models. The compound antagonized the sleep-inducing effects of clonidine in chicks and mice and it antagonized the mydriasis induced by clonidine in the rat. | [Uses]
Org 6906 is a monoamine reuptake inhibitor that promotes monoaminergic neurotransmission by inhibiting the reuptake of noradrenaline, dopamine, and serotonin. Org 6906 is also an α2 Adrenergic Receptor antagonist, with a pKi value of 6.3 (using the selective α2 adrenergic receptor ligand [3H]rauwolscine as a ligand). Org 6906 exhibits antidepressant activity and can be used in research related to neurological disorders[1]. | [IC 50]
α2-adrenergic receptor: 6.5 (pKi) | [References]
[1] de Boer T, et al. The pharmacological profile of Org 6906, a potential non-sedative antidepressant that combines monoamine uptake inhibition with alpha 2-adrenolytic activity. Neuropharmacology. 1988 Mar;27(3):251-60. DOI:10.1016/0028-3908(88)90041-x |
|
|